MRM open to part­ner­ships af­ter lead can­di­date im­press­es in PhI­Ia ul­cer­a­tive col­i­tis tri­al

MRM Health’s mi­cro­bio­me con­sor­tium ther­a­py for ul­cer­a­tive col­i­tis has shown promise in a Phase IIa tri­al, trig­ger­ing plans for late-stage de­vel­op­ment and po­ten­tial part­ner­ships.

The Bel­gian biotech’s study set the treat­ment, dubbed MH002, against place­bo in 45 peo­ple with mild-to-mod­er­ate UC.

MH002 pro­duced a 12% im­prove­ment in the Mayo En­do­scop­ic Sever­i­ty score, while the score wors­ened by 5% with place­bo (p=0.05). The treat­ment al­so hit sig­nif­i­cance in the end­point of stool con­sis­ten­cy im­prove­ment af­ter two weeks (p=0.006).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER